المؤلفون: Wilkinson, Nina, Tsakok, Teresa, Dand, Nick, Bloem, Karien, Duckworth, Michael, Baudry, David, Pushpa-Rajah, Angela, Griffiths, Christopher E.M., Reynolds, Nick J., Barker, Jonathan, Warren, Richard B., Burden, A. David, Rispens, Theo, Stocken, Deborah, Smith, Catherine

المصدر: Wilkinson, N, Tsakok, T, Dand, N, Bloem, K, Duckworth, M, Baudry, D, Pushpa-Rajah, A, Griffiths, C EM, Reynolds, N J, Barker, J, Warren, R B, Burden, A D, Rispens, T, Stocken, D & Smith, C 2019, ' Defining the therapeutic range for adalimumab and predicting response in psoriasis : a multicenter prospective observational cohort study ', Journal of Investigative Dermatology, vol. 139, no. 1, pp. 115-123 . https://doi.org/10.1016/j.jid.2018.07.028
The Journal of Investigative Dermatology

مصطلحات موضوعية: IMID, immune-mediated inflammatory disease, IBD, inflammatory bowel disease, Tumor Necrosis Factor-alpha, BADBIR, British Association of Dermatologists Biologic Interventions Registry, Adalimumab, RA, rheumatoid arthritis, Antibodies, Monoclonal, PASI, Psoriasis Area and Severity Index, Antibodies, Monoclonal, Humanized, Article, BSTOP, Biomarkers of Systemic Treatment Outcomes in Psoriasis, Etanercept, CI, confidence interval, PASI90, 90% improvement in baseline Psoriasis Area and Severity Index, Cohort Studies, PASI75, 75% improvement in baseline Psoriasis Area and Severity Index, Humans, Psoriasis, Prospective Studies, ADA, anti-drug antibody

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7fb02c669a37546deaa81518faf9005d
https://eprints.gla.ac.uk/212827/1/212827.pdf